Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results

Viking Therapeutics (VKTX) stock ripped higher on Sept. 22 after the biotech firm disclosed positive top-line results from its Phase 2 trial involving its lead dual GLP-1/GIP agonist — VK2735. The study showed up to 22% placebo-adjusted weight loss at 33 weeks and confirmed the viability of flexible monthly and biweekly dosing.

Following today’s surge, Viking Therapeutics stock is up roughly 8% versus the start of this year, but down the same from its July high.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.